Log in

NASDAQ:GNMKGenMark Diagnostics Stock Price, Forecast & News

$9.49
-0.14 (-1.45 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$9.09
Now: $9.49
$9.76
50-Day Range
$6.04
MA: $10.02
$12.84
52-Week Range
$3.36
Now: $9.49
$13.49
Volume1.46 million shs
Average Volume2.78 million shs
Market Capitalization$587.34 million
P/E RatioN/A
Dividend YieldN/A
Beta3.13
GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It also provides diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, thrombophilia risk test, a warfarin sensitivity test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.
Read More
GenMark Diagnostics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GNMK
CUSIPN/A
Phone760-448-4300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$88.02 million
Book Value$0.21 per share

Profitability

Net Income$-47,350,000.00

Miscellaneous

Employees477
Market Cap$587.34 million
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive GNMK News and Ratings via Email

Sign-up to receive the latest news and ratings for GNMK and its competitors with MarketBeat's FREE daily newsletter.

GenMark Diagnostics (NASDAQ:GNMK) Frequently Asked Questions

How has GenMark Diagnostics' stock been impacted by COVID-19 (Coronavirus)?

GenMark Diagnostics' stock was trading at $5.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GNMK stock has increased by 75.1% and is now trading at $9.49. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of GenMark Diagnostics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GenMark Diagnostics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for GenMark Diagnostics.

When is GenMark Diagnostics' next earnings date?

GenMark Diagnostics is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for GenMark Diagnostics.

How were GenMark Diagnostics' earnings last quarter?

GenMark Diagnostics, Inc (NASDAQ:GNMK) announced its quarterly earnings results on Monday, May, 4th. The medical equipment provider reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02. The medical equipment provider had revenue of $38.74 million for the quarter, compared to analysts' expectations of $38.70 million. GenMark Diagnostics had a negative net margin of 40.18% and a negative return on equity of 310.58%. View GenMark Diagnostics' earnings history.

What guidance has GenMark Diagnostics issued on next quarter's earnings?

GenMark Diagnostics issued an update on its FY 2020 After-Hours earnings guidance on Monday, May, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $120-130 million, compared to the consensus revenue estimate of $108.58 million.

What price target have analysts set for GNMK?

5 brokerages have issued 12 month price targets for GenMark Diagnostics' shares. Their forecasts range from $7.00 to $15.00. On average, they expect GenMark Diagnostics' stock price to reach $11.50 in the next year. This suggests a possible upside of 21.2% from the stock's current price. View analysts' price targets for GenMark Diagnostics.

Has GenMark Diagnostics been receiving favorable news coverage?

News stories about GNMK stock have been trending somewhat negative on Sunday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. GenMark Diagnostics earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutGenMark Diagnostics.

Are investors shorting GenMark Diagnostics?

GenMark Diagnostics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 2,890,000 shares, an increase of 19.4% from the April 15th total of 2,420,000 shares. Based on an average daily trading volume, of 2,600,000 shares, the days-to-cover ratio is currently 1.1 days. Approximately 5.1% of the shares of the stock are sold short. View GenMark Diagnostics' Current Options Chain.

Who are some of GenMark Diagnostics' key competitors?

What other stocks do shareholders of GenMark Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GenMark Diagnostics investors own include Inovio Pharmaceuticals (INO), Co-Diagnostics (CODX), Opko Health (OPK), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Novavax (NVAX), Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Arena Pharmaceuticals (ARNA) and Biocept (BIOC).

Who are GenMark Diagnostics' key executives?

GenMark Diagnostics' management team includes the following people:
  • Mr. Hany Massarany, CEO, Pres & Director (Age 58)
  • Mr. Scott Mendel, Chief Operating Officer (Age 52)
  • Mr. Michael Gleeson, Sr. VP of Corp. Accounts (Age 44)
  • Mr. John Frederick Ek, Chief Financial Officer (Age 43)
  • Mr. Eric Stier, Sr. VP, Gen. Counsel & Sec. (Age 43)

What is GenMark Diagnostics' stock symbol?

GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."

Who are GenMark Diagnostics' major shareholders?

GenMark Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Morgan Stanley (7.42%), Morgan Stanley (7.42%), BlackRock Inc. (6.97%), HighTower Advisors LLC (3.71%), Needham Investment Management LLC (2.33%) and State Street Corp (1.74%). Company insiders that own GenMark Diagnostics stock include Brian Andrew Mitchell, Eric Stier, Hany Massarany, James B Mcnally, John Frederick Ek, Kevin C Oboyle, Michael Gleeson, Michael John Harkins, Michael Kagnoff, Sarah Hollis Winkler, Scott Mendel and Tyler Jensen. View institutional ownership trends for GenMark Diagnostics.

Which major investors are selling GenMark Diagnostics stock?

GNMK stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Morgan Stanley, Morgan Stanley, Deutsche Bank AG, Wells Fargo & Company MN, Squarepoint Ops LLC, Essex Investment Management Co. LLC, and Two Sigma Advisers LP. Company insiders that have sold GenMark Diagnostics company stock in the last year include Brian Andrew Mitchell, Eric Stier, Hany Massarany, James B Mcnally, John Frederick Ek, Kevin C Oboyle, Michael Gleeson, Michael John Harkins, Sarah Hollis Winkler, Scott Mendel, and Tyler Jensen. View insider buying and selling activity for GenMark Diagnostics.

Which major investors are buying GenMark Diagnostics stock?

GNMK stock was purchased by a variety of institutional investors in the last quarter, including Portolan Capital Management LLC, Needham Investment Management LLC, Precept Management LLC, Russell Investments Group Ltd., IndexIQ Advisors LLC, Dupont Capital Management Corp, Dynamic Technology Lab Private Ltd, and Proficio Capital Partners LLC. Company insiders that have bought GenMark Diagnostics stock in the last two years include Kevin C Oboyle, and Michael Kagnoff. View insider buying and selling activity for GenMark Diagnostics.

How do I buy shares of GenMark Diagnostics?

Shares of GNMK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GenMark Diagnostics' stock price today?

One share of GNMK stock can currently be purchased for approximately $9.49.

How big of a company is GenMark Diagnostics?

GenMark Diagnostics has a market capitalization of $587.34 million and generates $88.02 million in revenue each year. The medical equipment provider earns $-47,350,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. GenMark Diagnostics employs 477 workers across the globe.

What is GenMark Diagnostics' official website?

The official website for GenMark Diagnostics is www.genmarkdx.com.

How can I contact GenMark Diagnostics?

GenMark Diagnostics' mailing address is 5964 LA PLACE COURT, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-448-4300 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.